Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.699 -0.051 (-2.89%)
Streaming Delayed Price Updated: 1:46 PM EDT, Mar 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Marijuana Stock Movers For August 15, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Enveric's Q2 2023 Financials Show Immediate Need For Budget-Slimming Toward A Clinical-Staged 2024
Next-gen psychedelics business Enveric Biosciences (NASDAQ: ENVB) reported its unaudited financial results for the second quarter of 2023 ended June 30. Results show: 
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Cannabis Stock Movers For August 3, 2023
Via Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
Marijuana Stock Movers For July 31, 2023
Via Benzinga
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
Cannabis Stock Gainers And Losers From July 28, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 25, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 26, 2023
Via Benzinga
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal... 
Via Benzinga
Enveric Unveils Positive Results From Preclinical Studies Supporting Metabolic Profile Of Its Psilocin Prodrug For Anxiety
Enveric Biosciences (NASDAQ: ENVB) announced successful completion of preclinical absorption, distribution, metabolism, and excretion (ADME) and toxicology studies conforming to earlier positive... 
Via Benzinga
Cannabis Stock Movers For July 24, 2023
Via Benzinga
Enveric Unveils Positive Results From Animal Studies Of Its Psilocin Prodrug For Anxiety
Enveric Biosciences (NASDAQ: ENVB) announced positive results from pharmacokinetic animal studies demonstrating oral bioavailability, rapid onset of action and systemic clearance, and a more favorable... 
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
Psychedelics Company Takes 'A Key Step' With New Formulation Of Its Psilocin Prodrug For Anxiety
Enveric Biosciences (NASDAQ: ENVB) announced the development of an improved formulation of EB-373 designed to enhance the drug product’s scalability, stability, and delivery for ongoing preclinical... 
Via Benzinga
Enveric Stock Trading Higher On Notice Of Allowance For Patent Application For Its Carboxylated Psilocybin Derivatives
Enveric Biosciences, Inc. (NASDAQ: ENVB) has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 series of... 
Via Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Enveric Biosciences Rallies 300% As It Receives US Patents For Psychedelic Compounds
Enveric Biosciences (ENVB) has recently received two patents for its novel psychedelic compounds, which are modeled from psilocybin mushrooms. 
Via Talk Markets
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR. 
Via Benzinga
Why Nutanix Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving Premarket
Gainers Nano Labs Ltd (NASDAQ: NA) shares rose 125% to $3.15 in pre-market trading. 
Via Benzinga
Crude Oil Rises 2%; Kohl's Reports Surprise Q1 Profit
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 250 points on Wednesday. The Dow traded down 0.73% to 32,813.21 while the NASDAQ fell 0.77% to 12,463.32. The S&P... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.